PG

Progyny, Inc.

PGNYHealthcareNASDAQ

Healthcare Plans

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$1.29B
+10.4% YoY
Net Income
$58.5M
+7.7% YoY
EBITDA
$90.2M
+27.7% YoY
Free Cash Flow
$200.9M

Scan Results

Daily timeframe
DateIndicatorDetails
Sep 3 MACD Positive CrossoverHistogram +0.0993, positive momentum
Sep 2 MACD Positive CrossoverHistogram +0.0363, positive momentum
About Progyny, Inc.

Part of the healthcare sector, Progyny, Inc. (PGNY) is listed under Healthcare Plans. At a $1.99B market cap, Progyny, Inc. ranks as a small-cap company within healthcare. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.

Where PGNY stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, PGNY finished 11.49% above its 150-day moving average ($23.58) and 9.04% above its 200-day moving average ($24.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is PGNY overbought or oversold?

At the September 3, 2026 close, PGNY's RSI(14) was 53.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.99B
P/E (TTM)28.20
Fwd P/E11.18
EPS$0.92
Beta0.99
52W Change+12.9%
ROE16.2%
Analysis

Progyny, Inc. holds $236.9M in cash against $22.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $200.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 16.2% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 10.1% further supports the picture of efficient asset utilization. Revenue has grown from $786.9M (2022) to $1.29B (2025), reflecting a 64% increase over the period.

With cash comfortably exceeding debt, PGNY has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PGNY.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms